Insider Transactions in Q1 2023 at Biogen Inc. (BIIB)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
116
-1.99%
|
$32,248
$278.03 P/Share
|
|
Mar 31
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
239
+3.95%
|
-
|
|
Mar 28
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
568
-16.66%
|
$153,360
$270.06 P/Share
|
|
Mar 02
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
687
-9.17%
|
$184,116
$268.75 P/Share
|
|
Mar 02
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+7.71%
|
-
|
|
Feb 17
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-4.37%
|
$64,774
$278.38 P/Share
|
|
Feb 17
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
480
+7.92%
|
-
|
|
Feb 17
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-3.82%
|
$41,978
$278.38 P/Share
|
|
Feb 17
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+10.43%
|
-
|
|
Feb 17
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-6.67%
|
$66,164
$278.38 P/Share
|
|
Feb 17
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
512
+11.76%
|
-
|
|
Feb 17
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,310
-14.73%
|
$364,180
$278.38 P/Share
|
|
Feb 17
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,561
+20.15%
|
-
|
|
Feb 17
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
371
-6.76%
|
$103,138
$278.38 P/Share
|
|
Feb 17
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
767
+11.53%
|
-
|
|
Feb 17
2023
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
929
-1.98%
|
$258,262
$278.38 P/Share
|
|
Feb 17
2023
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,920
+3.94%
|
-
|
|
Feb 17
2023
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-8.54%
|
$241,026
$278.38 P/Share
|
|
Feb 17
2023
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,792
+13.93%
|
-
|
|
Feb 10
2023
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,202
-2.93%
|
$1,201,772
$286.3 P/Share
|
|
Feb 10
2023
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,023
+4.02%
|
-
|
|
Feb 10
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,324
-7.07%
|
$378,664
$286.3 P/Share
|
|
Feb 10
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,968
+12.95%
|
-
|
|
Feb 10
2023
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
3,306
-8.92%
|
$945,516
$286.3 P/Share
|
|
Feb 10
2023
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,290
+11.51%
|
-
|
|
Feb 10
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
590
-5.07%
|
$168,740
$286.3 P/Share
|
|
Feb 10
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,061
+11.51%
|
-
|
|
Feb 10
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,105
-11.05%
|
$316,030
$286.3 P/Share
|
|
Feb 10
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,256
+24.56%
|
-
|
|
Feb 10
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-9.63%
|
$106,392
$286.3 P/Share
|
|
Feb 10
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,211
+23.87%
|
-
|
|
Feb 10
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
1,387
-7.55%
|
$396,682
$286.3 P/Share
|
|
Feb 10
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,611
+15.79%
|
-
|
|
Jan 25
2023
|
Priya Singhal Head of Development |
BUY
Grant, award, or other acquisition
|
Direct |
1,123
+29.75%
|
-
|
|
Jan 25
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
887
+22.26%
|
-
|
|
Jan 25
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Grant, award, or other acquisition
|
Direct |
1,783
+26.91%
|
-
|
|
Jan 25
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+24.6%
|
-
|
|
Jan 25
2023
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,703
+11.23%
|
-
|
|
Jan 25
2023
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
4,452
+30.46%
|
-
|